这是一篇来自已证抗体库的有关
人类 PRKCQ的综述,是根据11篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合PRKCQ 抗体。
PRKCQ 同义词: PRKCT; nPKC-theta
赛默飞世尔
domestic rabbit 重组(F4H4L1) | | 赛默飞世尔 PRKCQ抗体(Invitrogen, F4H4L1)被用于被用于免疫印迹在人类样本上 (图 5a). Mol Ther (2016) ncbi |
domestic rabbit 重组(F4H4L1) | | 赛默飞世尔 PRKCQ抗体(Invitrogen, 700043)被用于被用于免疫组化-石蜡切片在小鼠样本上 (图 5). Br J Pharmacol (2014) ncbi |
圣克鲁斯生物技术
小鼠 单克隆(E-7) | | 圣克鲁斯生物技术 PRKCQ抗体(Santa-Cruz Biotechnologies, sc-1680)被用于被用于免疫细胞化学在人类样本上 和 被用于免疫印迹在人类样本上. BMC Cell Biol (2014) ncbi |
赛信通(上海)生物试剂有限公司
domestic rabbit 多克隆 | | 赛信通(上海)生物试剂有限公司 PRKCQ抗体(Cell Signaling, 9377)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3e). EMBO Mol Med (2020) ncbi |
domestic rabbit 单克隆(E1I7Y) | | 赛信通(上海)生物试剂有限公司 PRKCQ抗体(Cell Signaling, 13643)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3e). EMBO Mol Med (2020) ncbi |
domestic rabbit 多克隆 | - 流式细胞仪; 人类; 1:200; 图 7b
- 免疫印迹; 人类; 1:1000; 图 7a
| 赛信通(上海)生物试剂有限公司 PRKCQ抗体(Cell Signaling, 9377)被用于被用于流式细胞仪在人类样本上浓度为1:200 (图 7b) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 7a). Nat Commun (2017) ncbi |
domestic rabbit 单克隆(E1I7Y) | | 赛信通(上海)生物试剂有限公司 PRKCQ抗体(Cell Signaling, E1I7Y)被用于被用于免疫印迹在人类样本上 (图 6e). PLoS Pathog (2017) ncbi |
domestic rabbit 多克隆 | | 赛信通(上海)生物试剂有限公司 PRKCQ抗体(Cell Signaling, 9377P)被用于被用于免疫印迹在人类样本上浓度为1:100 (图 st1). Nat Commun (2016) ncbi |
domestic rabbit 多克隆 | | 赛信通(上海)生物试剂有限公司 PRKCQ抗体(Cell signaling, 9377)被用于被用于免疫印迹在小鼠样本上 (图 6). PLoS ONE (2016) ncbi |
domestic rabbit 单克隆(E1I7Y) | | 赛信通(上海)生物试剂有限公司 PRKCQ抗体(Cell Signaling Technology, 13643)被用于被用于免疫印迹在小鼠样本上 (图 6). Cell Signal (2016) ncbi |
domestic rabbit 多克隆 | - 免疫印迹; 人类; 1:1000; 图 6
- 免疫印迹; 小鼠; 1:1000; 图 8
| 赛信通(上海)生物试剂有限公司 PRKCQ抗体(Cell signaling, 9377S)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 6) 和 被用于免疫印迹在小鼠样本上浓度为1:1000 (图 8). Nat Commun (2016) ncbi |
domestic rabbit 多克隆 | | 赛信通(上海)生物试剂有限公司 PRKCQ抗体(Cell Signaling Technology, 9377)被用于被用于免疫印迹在小鼠样本上 (图 5). Biochim Biophys Acta (2016) ncbi |
Fan Z, Tian Y, Chen Z, Liu L, Zhou Q, He J,
et al. Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. EMBO Mol Med. 2020;12:e11571
pubmed 出版商
Schober T, Magg T, Laschinger M, Rohlfs M, Linhares N, Puchalka J,
et al. A human immunodeficiency syndrome caused by mutations in CARMIL2. Nat Commun. 2017;8:14209
pubmed 出版商
Kinosada H, Yasunaga J, Shimura K, Miyazato P, Onishi C, Iyoda T,
et al. HTLV-1 bZIP Factor Enhances T-Cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors. PLoS Pathog. 2017;13:e1006120
pubmed 出版商
Treindl F, Ruprecht B, Beiter Y, Schultz S, Döttinger A, Staebler A,
et al. A bead-based western for high-throughput cellular signal transduction analyses. Nat Commun. 2016;7:12852
pubmed 出版商
Kim Y, Yadava R, Mandal M, Mahadevan K, Yu Q, Leitges M,
et al. Disease Phenotypes in a Mouse Model of RNA Toxicity Are Independent of Protein Kinase Cα and Protein Kinase Cβ. PLoS ONE. 2016;11:e0163325
pubmed 出版商
Ozay E, González Pérez G, Torres J, Vijayaraghavan J, Lawlor R, Sherman H,
et al. Intracellular Delivery of Anti-pPKC? (Thr538) via Protein Transduction Domain Mimics for Immunomodulation. Mol Ther. 2016;24:2118-2130
pubmed 出版商
Zhao W, Li A, Feng X, Hou T, Liu K, Liu B,
et al. Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. Cell Signal. 2016;28:1401-11
pubmed 出版商
Blas Rus N, Bustos Morán E, Perez de Castro I, de Carcer G, Borroto A, Camafeita E,
et al. Aurora A drives early signalling and vesicle dynamics during T-cell activation. Nat Commun. 2016;7:11389
pubmed 出版商
Pinel A, Rigaudière J, Laillet B, Pouyet C, Malpuech Brugère C, Prip Buus C,
et al. N-3PUFA differentially modulate palmitate-induced lipotoxicity through alterations of its metabolism in C2C12 muscle cells. Biochim Biophys Acta. 2016;1861:12-20
pubmed 出版商
Jia J, Martin T, Ye L, Jiang W. FAP-? (Fibroblast activation protein-?) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway. BMC Cell Biol. 2014;15:16
pubmed 出版商
Li Z, Abdullah C, Jin Z. Inhibition of PKC-? preserves cardiac function and reduces fibrosis in streptozotocin-induced diabetic cardiomyopathy. Br J Pharmacol. 2014;171:2913-24
pubmed 出版商